Key result
Acquired long QT syndrome is highly prevalent in chronic kidney disease patients and serves as an independent risk factor for sudden cardiac death and all-cause mortality.
Why the study?
Acquired long QT syndrome is prevalent and independently predicts sudden cardiac death and all-cause mortality in CKD patients, prompting a review to promote its management.
This review summarizes the epidemiology, mechanisms, and management of acquired long QT syndrome in patients with chronic kidney disease, emphasizing its role as an independent risk factor for sudden cardiac death.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in chronic kidney disease (CKD) patients. QT interval prolongation is a congenital or acquired condition that is associated with an increased risk of torsade de pointes (TdP), sudden cardiac death (SCD), and all-cause mortality in the general population. The prevalence of acquired long QT syndrome (aLQTS) is high, and various acquired conditions contribute to the prolonged QT interval in patients with CKD. More notably, the prolonged QT interval in CKD is an independent risk factor for SCD and all-cause mortality. In this review, we focus on the epidemiological characteristics, risk factors, underlying mechanisms and treatments of aLQTS in CKD, promoting the management of aLQTS in CKD patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted a review in Chronic kidney disease and acquired long QT syndrome. Acquired long QT syndrome was evaluated. Acquired long QT syndrome is highly prevalent in chronic kidney disease patients and serves as an independent risk factor for sudden cardiac death and all-cause mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: